✦ LIBER ✦

Tumor necrosis factor-alfa inhibitors and severe psoriasis: A “number needed to treat” analysis of the risks and benefits of treatment

Book ID: 116585230
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 43 KB
Volume: 60
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2008.11.708

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Using ‘number needed to treat’ to help c

Using ‘number needed to treat’ to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-α inhibitors for patients with severe psoriasis

✍ J.W. Dharamsi; M. Bhosle; R. Balkrishnan; B.A. Yentzer; S.R. Feldman 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB

PSS3 USING “NUMBER NEEDED TO TREAT” TO H

PSS3 USING “NUMBER NEEDED TO TREAT” TO HELP CONCEPTUALIZE THE MAGNITUDE OF BENEFIT AND RISK OF TNFÁ INHIBITORS FOR PATIENTS WITH SEVERE PSORIASIS

✍ J Warner; MJ Bhosle; R Balkrishnan; BA Yentzer; SR Feldman 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

Using ‘number needed to treat’ to expres

Using ‘number needed to treat’ to express the magnitudes of benefit of ultraviolet B phototherapy and of antitumour necrosis factor-α therapies for psoriasis

✍ R.S. Dawe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

How useful are cholinesterase inhibitors

How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis

✍ Gill Livingston; Cornelius Katona 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 2 views

Objectives. To report on a Numbers Needed to Treat (NNT) analysis of the literature identi®ed through a systematic review of trials of cholinesterase inhibitors in Alzheimer's Disease. Design. Search of Medline (1966±1998), EMBASE (1994±1999) and Psychlit (1974±1998) using the keywords cholinestera

The place of memantine in the treatment

The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis

✍ Gill Livingston; Cornelius Katona 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

## Abstract ## Introduction Memantine is currently the only treatment approved for moderately severe to severe Alzheimer's disease (AD). There is still some discussion as to its place in clinical practice and many UK clinicians are discouraged for economic reasons from prescribing it. We adopt a ‘

Pharmacodynamic and pharmacokinetic resp

Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris

✍ Alice B. Gottlieb; Salman Masuda; Rallapalli Ramamurthi; Ahsan Abdulghani; Pat R 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 255 KB